20
Participants
Start Date
April 5, 2024
Primary Completion Date
July 1, 2024
Study Completion Date
July 1, 2024
Microgynon
Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.
GSK3036656
Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.
GSK Investigational Site, Madrid
Lead Sponsor
GlaxoSmithKline
INDUSTRY